参考文献

1.Lourenço L C, Horta D V, Alberto S F, et al. Hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus and pulmonary emboli. Rev Esp Enferm Dig, 2017, 109(4):296-297.

2.Huang J, Pan ZY, Li L, et al. Hepatocellular carcinoma with inferior vena caval and right atrial tumor thrombi and massive pulmonary artery embolism: A case report.Mol Clin Oncol, 2017,6(1):111-114.

3.Ma H, Sun X, Chen L, et al. Multiplex immunochips for high-Accuracy detection of AFP-L3% based on surface-enhanced raman scattering: implications for early liver cancer diagnosis. Analytical Chemistry, 2017, 89(17):8877.

4.中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017版）.中华消化外科杂志,2017,16（7）：635-647.

5.Jia Z,Wang L,Liu C,et al. Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn),2014,18(3):192-196.

6.Zhang Z, Zhang Y, Wang Y, et al.Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma.Onco Targets Ther,2015,9:123-129.

7.Jing JS, Ye W, Jiang YK,et al. The value of GPC3 and GP73 in clinical diagnosis of hepatocellular carcinoma.Clin Lab, 2017,63(11):1903-1909.

8.Jia X,Liu J,Gao Y,et al.Diagnosis accuracy of glypocan-3 in patients with hepatocellular carcinom:asystematic review withmeta-analysis. Arch Med Res,2014,45(7):580-588.

9.Lim T S, Kim d Y, Han K H, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scandinavian Journal of Gastroenterology, 2016, 51(3):344-353.

10.Seo SI,Kim HS,Kim WJ,et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus–associated hepatocellular carcinoma. World J Gastroenterol,2015, 21(13): 3928- 3935.

11.Yu R, Tan Z, Xiang X, et al.Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.BMC Cancer, 2017，17(1):608.

12.Huang S, Jiang F, Wang Y, et al. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.Tumour Biol, 2017,39(6): 1010428317705763.

13.Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.Medicine (Baltimore),2017, 96(11): e5811.

14.Zhang Z, Zhang Y, Wang Y, et al.Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma.Onco Targets Ther,2015,9:123-129.

15.Yang J, Li J, Dai W, et al.Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis.Exp Ther Med,2015,9(4):1413-1420.

16.Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus.PLoS One,2014,9(9):e107986.

17.Lin XJ, Chong Y, Guo ZW, et al.A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol,2015,16(7):804-815.

18.Zhou J, Yu L,Gao X, et al.Plasma microRNA panel to diagnos hepatitis B virus-related hepatocellular carcinoma. J Clin Onecol, 2011,29(36):4781-4788.